Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancerKatsuhiko Nara, Yutaka Osuga, Ayumi Taguchi et al.|International Journal of Clinical Oncology|2023Cited by 3
Differential expression of human papilloma virus 16-, 18-, 52-, and 58-derived transcripts in cervical intraepithelial neoplasiaSatoshi Baba, Kei Kawana, Ayumi Taguchi et al.|Research Square|2020Cited by 1
Differential expression of human papillomavirus 16-, 18-, 52-, and 58-derived transcripts in cervical intraepithelial neoplasiaSatoshi Baba, Kei Kawana, Ayumi Taguchi et al.|Research Square|2020Cited by 0
Heterogeneous effects of cytotoxic chemotherapies for platinum-resistant ovarian cancerKatsuhiko Nara, Yutaka Osuga, Ayumi Taguchi et al.|Research Square|2023Cited by 0
A novel clinically applicable biomarker for testing HRD status based on the mutational signatures: Results for the phase 2 trial of olaparib maintenance monotherapy in patients with primary high-grade ovarian carcinoma (2271)Katsutoshi Oda, Hiroyuki Aburatani, Kosuke Yoshihara et al.|Gynecologic Oncology|2023Cited by 0